GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Short-Term Debt

H. Lundbeck AS (LTS:0ND5) Short-Term Debt : kr0 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Short-Term Debt?

H. Lundbeck AS's Short-Term Debt for the quarter that ended in Mar. 2024 was kr0 Mil.


H. Lundbeck AS Short-Term Debt Historical Data

The historical data trend for H. Lundbeck AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Short-Term Debt Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,000.00 2,000.00 - - -

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

H. Lundbeck AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


H. Lundbeck AS Short-Term Debt Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (LTS:0ND5) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines